Cadrenal Therapeutics, Inc. announced on September 24, 2026, that its stockholders approved an amendment to the company’s 2022 Successor Equity Incentive Plan. The amendment, referred to as Amendment No. 2, increases the total number of shares of common stock available for awards under the plan from 676,458 shares to 1,000,000 shares. This represents an increase of 323,542 shares.
The approval was finalized during the company’s 2026 Annual Meeting of Stockholders. According to the voting results, the Plan Amendment Proposal received 694,746 votes in favor, 352,409 votes against, and 6,853 abstentions.
The meeting also addressed other matters, including the election of directors and the ratification of the independent auditor. Additionally, stockholders approved the issuance of up to 960,000 shares of common stock upon the exercise of Series C-1 warrants issued in a private placement closing on July 1, 2026.
